Diabetes and antioxidants: Myth or reality?

Current Vascular Pharmacology

Volumn 8, Issue 5, 2010, Pages 661-672

  Haidara, Mohamed A ^a   Yassin, Hanaa Z ^b   Zakula, Zorica ^c   Mikhailidis, Dimitri P ^d   Isenovic, Esma R ^c  

^a KING KHALID UNIVERSITY   (Saudi Arabia)

^b CAIRO UNIVERSITY   (Egypt)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

antioxidants; Diabetes; oxidative stress; statins

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; FLAVINE MONONUCLEOTIDE; GLUCOSE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HEAT SHOCK PROTEIN 70; HIGH DENSITY LIPOPROTEIN; HYDROXYL RADICAL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RUBOXISTAURIN; SUPEROXIDE DISMUTASE; THIOCTIC ACID; VON WILLEBRAND FACTOR;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL VIABILITY; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DNA DAMAGE; DNA FRAGMENTATION; ELECTRON MICROSCOPY; ENDOTHELIUM CELL; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; HYPERGLYCEMIA; INCIDENCE; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; MORBIDITY; MORTALITY; MUSCLE CONTRACTILITY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PHAGOCYTOSIS; PROTEIN EXPRESSION; RESPIRATORY CHAIN; REVIEW; ANIMAL; DIABETIC ANGIOPATHY; DISEASE COURSE; METABOLISM; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTIOXIDANTS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; DISEASE PROGRESSION; HUMANS; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 79954620383     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016110792006941     Document Type: Review

References (158)

1. Clark CM Jr, Lee DA. Prevention and treatment of the complications of diabetes mellitus. N Engl J Med 1995; 332: 1210-7.
2. Singh JP, Larson MG, O'Donnell CJ, et al. Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). Am J Cardiol 2000; 86: 309-12.
3. Ganda OP. Pathogenesis of macrovascular disease in the human diabetic. Diabetes 1980; 29: 931-42.
4. Johansen JS, Harris AK, Rychly DJ, Ergul A. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol 2005; 4: 5.
5. Norman E, Cameron M, Cotter A. Metabolic and vascular Factors in pathogenesis of diabetic neuropathy. Diabetes 1997; 46 (Suppl 2): 531-7.
6. Vega-Lopez S, Devaraj S, Jialal I. Oxidative stress and antioxidant supplementation in the management of diabetic cardiovascular disease. J Investig Med 2004; 52: 24-32.
7. Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004; 65: 1009-16.
8. Guzik TJ, West NE, Black E, et al. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res 2000; 86: E85-90.
9. Guzik TJ, Mussa S, Gastaldi D, et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002; 105: 1656-62.
10. Ceriello A, Mercuri F, Quagliaro L, et al. Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 2001; 44: 834-8.
11. Turko IV, Marcondes S, Murad F. Diabetes-associated nitration of tyrosine and inactivation of succinyl-CoA:3-oxoacid CoAtransferase. Am J Physiol Heart Circ Physiol 2001; 281: H2289-94.
12. Aliciguzel Y, Ozen I, Aslan M, Karayalcin U. Activities of xanthine oxidoreductase and antioxidant enzymes in different tissues of diabetic rats. J Lab Clin Med 2003; 142: 172-7.
13. Soriano FG, Virag L, Szabo C. Diabetic endothelial dysfunction: role of reactive oxygen and nitrogen species production and poly(ADP-ribose) polymerase activation. J Mol Med 2001; 79: 437-48.
14. Kitada M, Koya D, Sugimoto T, et al. Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy. Diabetes 2003; 52: 2603-14.
15. Etoh T, Inoguchi T, Kakimoto M, et al. Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibility by interventive insulin treatment. Diabetologia 2003; 46: 1428-37.
16. Ergul A, Johansen JS, Stromhaug C, et al. Vascular dysfunction of venous bypass conduits is mediated by reactive oxygen species in diabetes: role of endothelin-1. J Pharmacol Exp Ther 2005; 313: 70-7.
17. Green K, Brand MD, Murphy MP. Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes 2004; 53 (Suppl 1): S110-8.
18. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-90.
19. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-20.
20. Haidara MA, Yassin HZ, Rateb M, Ammar H, Zorkani MA. Role of oxidative stress in development of cardiovascular complications in diabetes mellitus. Curr Vasc Pharmacol 2006; 4: 215-27
21. Bielecka-Dabrowa A, Barylski M, Mikhailidis DP, Rysz J, Banach M. HSP 70 and atherosclerosis--protector or activator? Expert Opin Ther Targets 2009; 13: 307-17.
22. Jeremy JY, Mikhailidis DP, Dandona P. Simulating the diabetic environment modifies in vitro prostacyclin synthesis. Diabetes 1983; 32: 217-21.
23. Haidara MA, Khloussy H, Ammar H, Aal Kassem LA. Impact of alpha-tocopherol and vitamin C on endothelial markers in rats with streptozotocin-induced diabetes. Med Sci Monit 2004; 10: BR41-6.
24. Haidara M, Desoky A, Khlousy H, Sebaee H. The mechanisms underlying the development of hypertension in STZ induceddiabetic rats. Prog Med Res 2004; 2: 30.
25. Koo JR, Ni Z, Oviesi F, Vaziri ND. Antioxidant therapy potentiates antihypertensive action of insulin in diabetic rats. Clin Exp Hypertens 2002; 24: 333-44.
26. Isomaa B, Henricsson M, Almgren P, Tuomi T, Taskinen MR, Groop L. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia 2001; 44: 1148-54.
27. Jiang ZY, Lin YW, Clemont A, et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 1999; 104: 447-57.
28. Minamikawa J, Yamauchi M, Inoue D, Koshiyama H. Another potential use of troglitazone in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1998; 83: 1041-2.
29. Natarajan R, Nadler JL. Lipoxygenases and lipid signaling in vascular cells in diabetes. Front Biosci 2003; 8: s783-95.
30. Halliwell B. Vitamin E and thetreatment and prevention of diabetes: a case for a controlled clinical trial. Singapore Med J 2002; 43: 479-84.
31. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008; 23: 370-8.
32. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999; 100: 1134-46.
33. Yoon SO, Kim MM, Park SJ, Kim D, Chung J, Chung AS. Selenite suppresses hydrogen peroxide-induced cell apoptosis through inhibition of ASK1/JNK and activation of PI3-K/Akt pathways. FASEB J 2002; 16: 111-3.
34. Ferdinandy P, Schulz R. Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 2003; 138: 532-43.
35. Dallak MM, Mikhailidis DP, Haidara MA, et al. Oxidative stress as a common mediator for apoptosis induced-cardiac damage in diabetic rats. Open Cardiovasc Med J 2008; 2: 70-8.
36. Ha H, Yu MR, Choi YJ, Kitamura M, Lee HB. Role of high glucose-induced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells. J Am Soc Nephrol 2002; 13: 894-902.
37. Alnaeb ME, Thompson CS, Seifalian AM, Hamilton G, Mikhailidis DP. Regional differences in the expression of nitric oxide synthase and specific receptors in the vascular tissues of control and diabetic rabbits: a pilot study. In jVivo 2007; 21: 1069-74.
38. Paraskevas KI, Bessias N, Papas TT, Gekas CD, Andrikopoulos V, Mikhailidis DP. Do different vascular risk factors affect all arteries equally? Angiology 2008; 59: 397-401.
39. Horie K, Miyata T, Maeda K, et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 1997; 100: 2995-3004.
40. Iino K, Iwase M, Sonoki K, Yoshinari M, Iida M. Combination treatment of vitamin C and desferrioxamine suppresses glomerular superoxide and prostaglandin E production in diabetic rats. Diabetes Obes Metab 2005; 7: 106-9.
41. Kedziora-Kornatowska K, Szram S, Kornatowski T, SzadujkisSzadurski L, Kedziora J, Bartosz G. Effect of vitamin E and vita-min C supplementation on antioxidative state and renal glomerular basement membrane thickness in diabetic kidney. Nephron Exp Nephrol 2003; 95: e134-43.
42. Zhang W, Khanna P, Chan LL, Campbell G, Ansari NH. Diabetes induced apoptosis in rat kidney. Biochem Mol Med 1997; 61: 5862.
43. Murata I, Takemura G, Asano K, et al. Apoptotic cell loss following cell proliferation in renal glomeruli of Otsuka Long-Evans Tokushima Fatty rats, a model of human type 2 diabetes. Am J Nephrol 2002; 22: 587-95.
44. Buttke TM, Sandstrom PA. Oxidative stress as a mediator of apoptosis. Immunol Today 1994; 15: 7-10.
45. Allen DA, Harwood S, Varagunam M, Raftery MJ, Yaqoob MM. High glucose-induced oxidative stress causes apoptosis in proximal tubular epithelial cells and is mediated by multiple caspases. FASEB J 2003; 17: 908-10.
46. Verzola D, Bertolotto MB, Villaggio B, et al. Taurine prevents apoptosis induced by high ambient glucose in human tubule renal cells. J Invest Med 2002; 50: 443-51.
47. Ishii N, Ogawa Z, Suzuki K, Numakami K, Saruta T, Itoh H. Glucose loading induces DNA fragmentation in rat proximal tubular cells. Metabolism 1996; 45: 1348-53.
48. Ortiz A, Ziyadeh FN, Neilson EG. Expression of apoptosis regulatory genes in renal proximal tubular epithelial cells exposed to high ambient glucose and in diabetic kidneys. J Investig Med 1997; 45: 50-6.
49. Caramori ML, Kim Y, Huang C, et al. Cellular basis of diabetic nephropathy: 1. Study design and renal structural-functional relationships in patients with long-standing type 1 diabetes. Diabetes 2002; 51: 506-13.
50. Mauer M, Drummond K. The International Diabetic Nephropathy Study Group: The early natural history of nephropathy in type 1 diabetes. 1. Study design and baseline characteristics of the study participants. Diabetes 2000; 51: 1572-9.
51. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science [75] 1996; 272: 728-31.
52. Haidara MA, Mikhailidis DP, Rateb MA, et al. Evaluation of the effect of oxidative stress and vitamin E supplementation on renal function in rats with streptozotocin-induced type 1 diabetes. J Diabetes Complications 2009; 23: 130-6.
53. Lawler JM, Powers SK. Oxidative stress, antioxidant status, and the contracting diaphragm. Can J Appl Physiol 1998; 23: 23-55.
54. Meydani M, Evans W, Handelman G, et al. Antioxidant response to exercise-induced oxidative stress and protection by vitamin E. Ann N Y Acad Sci 1992; 669: 363-4.
55. Haidara MA, Ibrahim IM, Al-Tuwaijri AS, Awadalla SA, Yaseen H. Effect of alpha-tocopherol on glucose uptake and contractility in rat skeletal muscle. Med Sci Monit 2003; 9: BR174-7.
56. Cesari M, Pahor M, Bartali B, et al. Antioxidants and physical performance in elderly persons: the Invecchiare in Chianti (InCHI-ANTI) study. Am J Clin Nutr 2004; 79: 289-94.
57. Diaz PT, She ZW, Davis WB, Clanton TL. Hydroxylation of salicylate by the in vitro diaphragm: evidence for hydroxyl radical production during fatigue. J Appl Physiol 1993; 75: 540-5.
58. Reid MB. Nitric oxide, reactive oxygen species, and skeletal muscle contraction. Med Sci Sports Exerc 2001; 33: 371-6.
59. Baydas G, Canatan H, Turkoglu A. Comparative analysis of the protective effects of melatonin and vitamin E on streptozotocininduced diabetes mellitus. J Pineal Res 2002; 32: 225-30.
60. Karasu C, Ozansay G, Bozkurt O. Antioxidant and triglyceridelowering effects of vitamin E associated with the prevention of abnormalities in the reactivity and morphology of aorta from streptozotocin-diabetic rats. Antioxidants in Diabetes-Induced Complications (ADIC) Study Group. Metabolism 1997; 46: 872-79.
61. Sies H, Stahl W. Reproducibility and validity of the diet quality index revised as assessed by use of food frequency questionnaire. Am J Clin Nutr 1995; 62 (Suppl): S-1315.
62. Verhoven B, Schlegel RA, Williamson P. Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes. J Exp Med 1995; 182: 1597-601.
63. Melhem MF, Craven PA, Derubertis FR. Effects of dietary supplementation of alpha-lipoic acid on early glomerular injury in diabetes mellitus. J Am Soc Nephrol 2001; 12: 124-33.
64. Cao G, Booth SL, Sadowski JA, Prior RL. Increases in human plasma antioxidant capacity after consumption of controlled diets high in fruit and vegetables. Am J Clin Nutr 1998; 68: 1081-7.
65. Breimer LH, Mikhailidis DP. Bilirubin and peripheral arterial disease: 15 years later. Expert Opin Ther Targets 2009; 13: 139-40.
66. Ganotakis ES, Vrentzos GE, Gazi IF, et al. Fibrinogen, lipoprotein (a), albumin and bilirubin (F-L-A-B) levels and cardiovascular risk calculated using the Framingham equation. In Vivo 2007; 21: 68594.
67. Chen L, Jia RH, Qiu CJ, Ding G. Hyperglycemia inhibits the uptake of dehydroascorbate in tubular epithelial cell. Am J Nephrol 2005; 25: 459-65.
68. Lahdenkari AT, Lounatmaa K, Patrakka J, et al. Podocytes are firmly attached to glomerular basement membrane in kidneys with heavy proteinuria. J Am Soc Nephrol 2004; 15: 2611-8.
69. Mekinova D, Chorvathova V, Volkovova K, et al. Effect of intake of exogenous vitamins C, E and beta-carotene on the antioxidative status in kidneys of rats with streptozotocin-induced diabetes. Nahrung 1995; 39: 257-61.
70. Boullier A, Bird DA, Chang MK, et al. Scavenger receptors, oxidized LDL, and atherosclerosis. Ann N Y Acad Sci 2001; 947: 214-22; discussion 222-3.
71. Maritim AC, Sanders RA, Watkins JB, 3rd. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 2003; 17: 24-38.
72. Shukla N, Thompson CS, Angelini GD, Mikhailidis DP, Jeremy JY. Low micromolar concentrations of copper augment the impairment of endothelium-dependent relaxation of aortae from diabetic rabbits. Metabolism 2004; 53: 1315-21.
73. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 2003; 108: 1912-6.
74. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation 2003; 108: 2034-40.
75. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 2003; 42: 1075-81.
76. Kaul N, Siveski-Iliskovic N, Hill M, Khaper N, Seneviratne C, Singal PK. Probucol treatment reverses antioxidant and functional deficit in diabetic cardiomyopathy. Mol Cell Biochem 1996; 160161: 283-8.
77. Hayden MR, Tyagi SC. Myocardial redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and congestive heart failure. Med Sci Monit 2003; 9: SR35-52.
78. Linke A, Adams V, Schulze PC, et al. Antioxidative effects of exercise training in patients with chronic heart failure: increase in radical scavenger enzyme activity in skeletal muscle. Circulation 2005; 111: 1763-70.
79. Polidori MC, Pratico D, Savino K, Rokach J, Stahl W, Mecocci P. Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity. J Card Fail 2004; 10: 334-8.
80. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a causal antioxidant therapy. Diabetes Care 2003; 26: 1589-96.
81. Cuzzocrea S, Riley DP, Caputi AP, Salvemini D. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev 2001; 53: 135-59.
82. Nassar T, Kadery B, Lotan C, Da'as N, Kleinman Y, Haj-Yehia A. Effects of the superoxide dismutase-mimetic compound tempol on endothelial dysfunction in streptozotocin-induced diabetic rats. Eur J Pharmacol 2002; 436: 111-8.
83. Coppey LJ, Gellett JS, Davidson EP, et al. Effect of M40403 treatment of diabetic rats on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve. Br J Pharmacol 2001; 134: 21-9.
84. Packer L, Valenza M, Serbinova E, Starke-Reed P, Frost K, Kagan V. Free radical scavenging is involved in the protective effect of L-propionyl-carnitine against ischemia-reperfusion injury of theheart. Arch Biochem Biophys 1991; 288: 533-7.
85. Broderick TL, Haloftis G, Paulson DJ. L-propionylcarnitine enhancement of substrate oxidation and mitochondrial respiration in the diabetic rat heart. J Mol Cell Cardiol 1996; 28: 331-40.
86. Vanella A, Russo A, Acquaviva R, et al. L -propionyl-carnitine as superoxide scavenger, antioxidant, and DNA cleavage protector. Cell Biol Toxicol 2000; 16: 99-104.
87. Felix C, Gillis M, Driedzic WR, Paulson DJ, Broderick TL. Effects of propionyl-L-carnitine on isolated mitochondrial function in the reperfused diabetic rat heart. Diabetes Res Clin Pract 2001; 53: 1724.
88. Cotter MA, Cameron NE, Keegan A, Dines KC. Effects of acetyland proprionyl-L-carnitine on peripheral nerve function and vascular supply in experimental diabetes. Metabolism 1995; 44: 1209-14.
89. Hensley K, Robinson KA, Gabbita SP, Salsman S, Floyd RA. Reactive oxygen species, cell signaling, and cell injury. Free Radic Biol Med 2000; 28: 1456-62.
90. Hensley K, Benaksas EJ, Bolli R, et al. New perspectives on vitamin E: gamma-tocopherol and carboxyelthylhydroxychroman metabolites in biology and medicine. Free Radic Biol Med 2004; 36: 1-15.
91. Gisinger C, Jeremy J, Speiser P, Mikhailidis D, Dandona P, Schernthaner G. Effect of vitamin E supplementation on platelet thromboxane A2 production in type I diabetic patients. Doubleblind crossover trial. Diabetes 1988; 37: 1260-4.
92. Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 2002; 56: 1137-42.
93. Hodgson JM, Watts GF. Can coenzyme Q10 improve vascular function and blood pressure? Potential for effective therapeutic reduction in vascular oxidative stress. Biofactors 2003; 18: 129-36.
94. Watts GF, Playford DA, Croft KD, Ward NC, Mori TA, Burke V. Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in type II diabetes mellitus. Diabetologia 2002; 45: 420-6.
95. Heller R, Unbehaun A, Schellenberg B, Mayer B, WernerFelmayer G, Werner ER. L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem 2001; 276: 40-7.
96. Coppey LJ, Gellett JS, Davidson EP, Dunlap JA, Lund DD, Yorek MA. Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes 2001; 50: 1927-37.
97. Heitzer T, Finckh B, Albers S, Krohn K, Kohlschutter A, Meinertz T. Beneficial effects of alpha-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Radic Biol Med 2001; 31: 53-61.
98. Soriano FG, Pacher P, Mabley J, Liaudet L, Szabo C. Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. Circ Res 2001; 89: 68491.
99. Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabo E, Szabo C. The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 2002; 51: 514-21.
100. Szabo C, Mabley JG, Moeller SM, et al. Part I: pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst. Mol Med 2002; 8: 571-80.
101. Kowluru RA. Diabetes-induced elevations in retinal oxidative stress, protein kinase C and nitric oxide are interrelated. Acta Diabetol 2001; 38: 179-85.
102. Garcia Soriano F, Virag L, Jagtap P, et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 2001; 7: 108-13.
103. Szabo C, Virag L, Cuzzocrea S, et al. Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase. Proc Natl Acad Sci USA 1998; 95: 3867-72.
104. Oliver FJ, Menissier-de Murcia J, Nacci C, et al. Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J 1999; 18: 4446-54.
105. Virag L, Salzman AL, Szabo C. Poly(ADP-ribose) synthetase activation mediates mitochondrial injury during oxidant-induced cell death. J Immunol 1998; 161: 3753-9.
106. Li M, Pascual G, Glass CK. Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol Cell Biol 2000; 20: 4699-707.
107. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-9.
108. Varin R, Mulder P, Tamion F, et al. Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure: role of nitric oxide, prostanoids, oxidant stress, and bradykinin. Circulation 2000; 102: 351-6.
109. Zhang H, Schmeisser A, Garlichs CD, et al. Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc Res 1999; 44: 215-22.
110. Wassmann S, Baumer AT, Strehlow K, et al. Endothelial dysfunction and oxidative stress during estrogen deficiency in spontaneously hypertensive rats. Circulation 2001; 103: 435-41.
111. Munzel T, Keaney JF Jr. Are ACE inhibitors a magic bullet against oxidative stress? Circulation 2001; 104: 1571-4.
112. Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation 2002; 105: 393-6.
113. Gabriely I, Yang XM, Cases JA, Ma XH, Rossetti L, Barzilai N. Hyperglycemia modulates angiotensinogen gene expression. Am J Physiol Regul Integr Comp Physiol 2001; 281: R795-802.
114. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998; 351: 28-31.
115. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355: 253-9.
116. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 85160.
117. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
118. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8.
119. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-10.
120. Ceriello A, Motz E. Angiotensin-receptor blockers, type 2 diabetes, and renoprotection. N Engl J Med 2002; 346: 705-7.
121. Onozato ML, Tojo A, Goto A, Fujita T, Wilcox CS. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int 2002; 61: 186-94.
122. Gorlach A, Brandes RP, Nguyen K, Amidi M, Dehghani F, Busse R. A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res 2000; 87: 26-32.
123. Berry C, Anderson N, Kirk AJ, Dominiczak AF, McMurray JJ. Renin angiotensin system inhibition is associated with reduced free radical concentrations in arteries of patients with coronary heart disease. Heart 2001; 86: 217-20.
124. Hamaty M, Guzman CB, Walsh MF, Bode AM, Levy J, Sowers JR. High glucose-enhanced acetylcholine stimulated CGMP masks impaired vascular reactivity in tail arteries from short-term hyperglycemic rats. Int J Exp Diabetes Res 2000; 1: 69-79.
125. Sowers JR. Common pathophysiological issue in diabetes and cardiovascular disease. Cardiol Rev 2000; 17: 13-23.
126. Sowers JR, Lester M. Hypertension, hormones, and aging. J Lab Clin Med 2000; 135: 379-86.
127. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypetension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Excetive Committees Working Group. Am J Kidney Dis 2000; 36: 645-61.
128. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes andin nondiabetic subjects with and without prior myocardial infarc[143] tion. N Engl J Med 1998; 339: 229-34.
129. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001; 86: 713-8.
130. Gazi IF, Tsimihodimos V, Tselepis AD, Elisaf M, Mikhailidis DP. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther 2007; 7: 53-72.
131. Takayama T, Wada A, Tsutamoto T, et al. Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor. Circ J [146] 2004; 68: 1067-75.
132. Haendeler J, Hoffmann J, Zeiher AM, Dimmeler S. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins. Circulation 2004; 110: 856-61.
133. Deakin S, Leviev I, Guernier S, James RW. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol 2003; 23: 2083-9.
134. Wassmann S, Laufs U, Baumer AT, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 2001; 59: 646-54.
135. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000; 20: 61-9.
136. Tziomalos K, Kakafika AI, Athyros VG, Karagiannis A, Mikhailidis DP. The role of statins for the primary and secondary prevention of coronary heart disease in women. Curr Pharm Des 2009; 15: 1054-62.
137. Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Pleiotropic effects of statins--clinical evidence. Curr [153] Pharm Des 2009; 15: 479-89.
138. Paraskevas KI, Stathopoulos V, Mikhailidis DP. Pleiotropic effects of statins: implications for a wide range of diseases. Curr Vasc Pharmacol 2008; 6: 237-9.
139. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101: 2711-9.
140. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothe[156] lial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-35.
141. Brandes RP, Behra A, Lebherz C, Boger RH, Bode-Boger SM, Mugge A. Lovastatin maintains nitric oxide--but not EDHF mediated endothelium-dependent relaxation in the hypercholesterolemic rabbit carotid artery. Atherosclerosis 1999; 142: 97-104.
142. Alvarez de Sotomayor M, Perez-Guerrero C, Herrera MD, Marhuenda E. Effects of chronic treatment with simvastatin on endothelial dysfunction in spontaneously hypertensive rats. J Hypertens 1999; 17: 769-76.
143. Muniyappa R, Xu R, Ram JL, Sowers JR. Inhibition of Rho protein stimulates iNOS expression in rat vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2000; 278: H1762-8.
144. Chen H, Ikeda U, Shimpo M, Ikeda M, Minota S, Shimada K. Fluvastatin upregulates inducible nitric oxide synthase expression in cytokine-stimulated vascular smooth muscle cells. Hypertension 2000; 36: 923-8.
145. 2+ currents and not endothelial nitric oxide production. Diabetes 1997; 46: 659-64.
146. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37: 1053-9.
147. 2+ and NO. Am J Physiol 1998; 275: H823-30.
148. Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003; 19: 540-56.
149. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994; 330: 1029-35.
150. Tardif JC, Cote G, Lesperance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med 1997; 337: 36572.
151. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
152. Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH. Betacarotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J Natl Cancer Inst 1999; 91: 2102-6.
153. Cheung MC, Zhao XQ, Chait A, Albers JJ, Brown BG. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol 2001; 21: 1320-6.
154. Kuller LH. A time to stop prescribing antioxidant vitamins to prevent and treat heart disease? Arterioscler Thromb Vasc Biol 2001; 21: 1253.
155. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583-92.
156. Tribble DL. AHA Science Advisory. Antioxidant consumption and risk of coronary heart disease: emphasis on vitamin C, vitamin E, and beta-carotene: A statement for healthcare professionals from the American Heart Association. Circulation 1999; 99: 591-5.
157. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19: 257-67.
158. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004; 24: 816-23.